Enovis Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENOV research report →
Range $27 – $45
Price Chart
About the company
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment.
- CEO
- Damien McDonald
- IPO
- 2008
- Employees
- 7,802
- HQ
- Lewisville, TX, US
Get TickerSpark's AI analysis on ENOV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.47B
- P/E
- -2.93
- Fwd P/E
- 6.89
- PEG
- -0.04
- P/S
- 0.68
- P/B
- 1.05
- EV/EBITDA
- -17.61
- Div Yield
- 0.00%
- Gross Margin
- 59.49%
- Op Margin
- 3.87%
- Net Margin
- -22.87%
- ROE
- -35.53%
- ROIC
- 2.78%
Latest fiscal year · YoY change
- Revenue
- $2.25B+6.7%
- Gross Profit
- $1.35B+13.9%
- Op Income
- $-18,869,000
- Net Income
- $-1,184,440,000-43.5%
- EPS
- $-20.86-39.7%
- OCF Growth
- +91.4%
- FCF Growth
- +129.6%
- 52W High
- $31.67
- 52W Low
- $16.70
- 50D MA
- $21.17
- 200D MA
- $23.33
- Beta
- 1.42
- RSI (14)
- 55
- Avg Volume
- 1.70M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Innovus delivered 5% organic growth, improved margins and cash flow, and raised full-year guidance while leaning into robotics and share repurchases.· November 5, 2026
- Q3 sales were $559 million, up 2% reported and 5% organic; adjusted EPS was $0.88, up 17% year over year.
- Adjusted gross margin was 60.9%, up 60 basis points, and adjusted EBITDA margin was 18.5%, up 120 basis points.
- Full-year guidance was raised: revenue to $2.32 billion-$2.35 billion, adjusted EBITDA to $428 million-$438 million, and adjusted EPS to $3.58-$3.79.
- Free cash flow improved sharply to $35 million in Q3 and $37 million year to date; management reiterated >25% free cash flow conversion for 2026.
- Management said markets remain choppy, especially U.S. hips and knees and international, but sees share gains, ASC growth, and Essential Robotics as key longer-term drivers.
Third-quarter sales were $559 million, up 2% reported and 5% organically. Organic growth was 6% in Recon and 3% in P&R. Adjusted gross margin was 60.9%, up 60 basis points year over year, adjusted EBITDA margin was 18.5%, and adjusted EPS was $0.88, up 17% versus prior year. Free cash flow was $35 million in the quarter and $37 million year to date, up $50 million versus the prior year. For full year 2026, the company narrowed revenue guidance to $2.32 billion-$2.35 billion, expects organic growth of approximately 5%, raised adjusted EBITDA guidance to $428 million-$438 million, and raised adjusted EPS guidance to $3.58-$3.79. Management also said Q4 should see modest acceleration driven by Arvis and shoulder, continued Nebula conversions, and new P&R products, with about $4 million of incremental enabling-technology R&D investment and a $1 million FX headwind.
Damien McDonald emphasized that the quarter showed solid execution in a volatile market, with 5% organic growth and share gains across Recon and P&R. He highlighted Nebula, Arvis shoulder expansion, and international shoulder strength as evidence that the recon portfolio is gaining traction, and said the company is early in a multiyear product cycle. He framed Essential Robotics as an inflection point, saying the acquisition can help build an enabling-technology ecosystem and support sustained above-market growth.
Ben Berry led with the numbers: $559 million in sales, 60.9% adjusted gross margin, 18.5% adjusted EBITDA margin, $0.88 adjusted EPS, and $35 million of free cash flow in Q3. He said gross margin benefited from mix, productivity, and $8 million of tariff refunds, partially offset by about $3 million of inflationary pressure tied to raw materials and freight/distribution costs from the Middle East conflict. He also said net leverage ended at 2.9x, the board approved a new $200 million share repurchase program, and the company expects leverage to step up by about 0.5 turn when Essential closes while staying within a 2.5x to 3.5x range.
Analysts pressed management on softness in U.S. hips and knees, with questions about market volatility, cancellations, and patient deferrals. Management said it is seeing 'all of the above' and is focused on market share, disciplined pricing, and salesforce execution rather than trying to predict the market. Questions also focused on free cash flow durability, ASC penetration, shoulder competition, and the margin outlook; management said ASC use is rising, shoulder remains competitively strong, and buybacks are being used opportunistically because the stock is viewed as dislocated relative to value.
The bull case from this call is that the company is still growing above the market despite a choppy backdrop, with share gains in Recon and a stronger P&R business. Management sounded confident that Arvis, Nebula, and Essential Robotics can extend the product cycle and support continued above-market growth, while cash generation and leverage remain improving.
The main risks discussed were volatile market conditions, especially in U.S. hips and knees and in international markets, plus conflict-related pressure in the Middle East. Management also acknowledged pricing pressure, some softness in foot and ankle and U.S. shoulder timing dynamics, and said it will spend an additional $4 million in Q4 on enabling-technology R&D ahead of the Essential deal.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.5%
- Shares Outstanding
- 57.69M
- Float Shares
- 56.26M
of shares held by institutions
262 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 10.30M | ▲ 359.20K |
| American Century Companies Inc | 6.89M | ▲ 783.34K |
| Vanguard Group Inc | 6.44M | ▼ 85.64K |
| Vanguard Portfolio Management LLC | 3.93M | ▲ 117.64K |
| Rubric Capital Management LP | 3.90M | ▲ 1.45M |
| State Street Corp | 2.50M | ▲ 38.85K |
| Vanguard Capital Management LLC | 2.48M | ▼ 68.03K |
| Dimensional Fund Advisors LP | 2.34M | ▲ 593.48K |
| Hood River Capital Management LLC | 2.30M | ▲ 542.66K |
| Private Management Group Inc | 1.79M | ▲ 427.35K |
| Goldman Sachs Group Inc | 1.77M | ▲ 204.43K |
| Geode Capital Management, LLC | 1.50M | ▼ 447 |
Held by 328 ETFs
Biggest fund positions in ENOV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Lalor Angela S | buy | 880 |
| Nov 12, 26 | Lalor Angela S | buy | 500 |
| Nov 12, 26 | Lalor Angela S | buy | 374 |
| Nov 11, 26 | Wienbar Sharon L | buy | 900 |
| Nov 10, 26 | Wienbar Sharon L | buy | 874 |
| Nov 11, 26 | Lalor Angela S | buy | 870 |
| Nov 10, 26 | Lalor Angela S | buy | 887 |
| Nov 9, 26 | Wienbar Sharon L | buy | 924 |
| Nov 6, 26 | Wienbar Sharon L | buy | 907 |
| Sep 30, 26 | Ortiz Christine | other | 958 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENOV coverage
Recent articles, reports, and earnings notes.
No research on ENOV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENOV report →Enovis to Present at the Annual Jefferies Global Healthcare Concerence in London
globenewswire.com · Nov 12
What Enovis (ENOV) Said on Its Q3 Earnings Call
marketbeat.com · Nov 7
Enovis Corporation (ENOV) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 5
ENOVIS Announces Third Quarter 2026 Results
globenewswire.com · Nov 5
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
globenewswire.com · Oct 8
electroCore (NASDAQ:ECOR) and Enovis (NYSE:ENOV) Head-To-Head Comparison
defenseworld.net · Oct 6
Critical Survey: Enovis (NYSE:ENOV) vs. Nexalin Technology (NASDAQ:NXL)
defenseworld.net · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.